Commentary: Neoadjuvant treatment of resectable pancreatic cancer: Lack of level III evidence

Surgery. 2020 Dec;168(6):1015-1016. doi: 10.1016/j.surg.2020.07.033. Epub 2020 Aug 29.

Authors

Martin Schneider¹, John P Neoptolemos¹, Markus W Büchler²

Affiliations

¹ Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Germany.
² Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Germany. Electronic address: markus.buechler@med.uni-heidelberg.de.

PMID: 32873411
DOI: 10.1016/j.surg.2020.07.033

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adenocarcinoma, Mucinous*
Humans
Neoadjuvant Therapy
Neoplasm Staging
Pancreatic Neoplasms* / surgery
Prognosis